NEJM Evidence publishes positive results from pivotal bladder cancer clinical trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Positive results from the phase II/III QUILT 3.032 trial studying N-803 (nogapendekin alfa inbakicept), a novel IL-15 superagonist complex, plus BCG in adults with non-muscle invasive bladder cancer carcinoma in situ with or without Ta/T1 papillary disease were published in NEJM Evidence.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login